|1.||Malinovskaia, V V: 5 articles (01/2013 - 01/2008)|
|2.||Vasil'ev, A N: 4 articles (01/2009 - 01/2008)|
|3.||Hehlmann, R: 2 articles (06/2015 - 06/2003)|
|4.||Voronina, F V: 2 articles (01/2009 - 01/2008)|
|5.||Gatich, R Z: 2 articles (01/2009 - 01/2008)|
|6.||Isaeva, E I: 2 articles (01/2009 - 01/2008)|
|7.||Orlova, T G: 2 articles (01/2009 - 01/2008)|
|8.||Parfenov, V V: 2 articles (01/2009 - 01/2008)|
|9.||Kolobukhina, L V: 2 articles (01/2009 - 01/2008)|
|10.||Burtseva, E I: 2 articles (01/2009 - 01/2008)|
11/25/2001 - "Collectively, the results indicate that human IFN-beta is superior to IFN-alpha 2 in antagonizing herpes simplex virus type 1 infection."
09/01/1983 - "The results suggest that intranasal IFN-alpha 2 may prove to be a safe and effective method of preventing rhinovirus infection and illness."
03/01/1983 - "In studies of interferon-alpha 2 treated volunteers with experimental rhinovirus infection, we determined that incorporation of antiinterferon antibody into collection broth significantly increased isolation rates (84% increase) and the proportion of monolayers positive for CPE (155% increase), as compared to plain collection broth."
04/01/1995 - "Sequential analysis indicated that reversion to IFN-alpha 2 sensitivity could occur during the course of infection."
12/01/1990 - "Transcript levels for IFN-alpha 1 and IFN-alpha 2 were equivalently induced in virus-infected U937 and U9-IIIB cells, indicating that a generalized derepression of cytokine gene expression did not occur as a consequence of HIV-1 infection. "
|2.||Chronic Hepatitis C
06/01/2007 - "The treatment of patients with chronic hepatitis C has rapidly evolved in the past 10 years centered on the use of interferon alpha 2 as an antiviral and immunomodulatory agent against hepatitis C virus. "
01/01/2009 - "Pegylated interferon alpha 2 (a or b) plus ribavirin is the most effective treatment of chronic hepatitis C but a large proportion of patients do not respond to therapy. "
06/07/2002 - "27 adult patients of the average age 46 years were cured from 1997 through 1999 for the histologically verified chronic hepatitis C with IFN-alpha 2 and ribavirin. "
01/01/2004 - "A cohort of 87 chronic hepatitis C patients submitted to therapy with interferon alpha 2 and ribavirin were followed from August 1999 to August 2002. "
03/01/1995 - "Recombinant interferon alfa (r-IFN alpha 2) has been shown to normalize the aminotransferase levels in approximately 50% of patients with chronic hepatitis C virus (HCV). "
|3.||Human Influenza (Influenza)
01/01/2009 - "[Viferon efficacy in influenza in adult patients]."
01/01/2008 - "Viferon can be recommended for the treatment of influenza in adults."
01/01/2008 - "[Viferon suppositories in the treatment of influenza in adults]."
01/01/2003 - "It is noteworthy, that a selection of RMF adequate for an actual nosologic form or of an administration method can reduce the medication dose of interferon-alpha 2 (thus, the incidence of complications to the drug goes down), it can also eliminate the influenza-like syndrome and production of autoantibodies related with the intramuscular administration of interferon-alpha 2, besides, it essentially prolongs the presence of interferon-alpha 2 in the body. "
01/01/1984 - "Recombinant DNA-produced human interferon-alpha 2 inhibited the replication of influenza A and B viruses in primary rhesus monkey kidney cells (RMK). "
|4.||Respiratory Tract Infections (Respiratory Tract Infection)
07/01/2002 - "Thus, Viferon appears promising as part of a complex therapy for children with BA at remission stages and frequent respiratory infections."
01/01/2008 - "The main tasks of the study were development of schemes and methods for prophylactic use of the Viferon ointment and estimation of its efficacy in acute viral respiratory tract infection. "
01/01/2008 - "[Viferon ointment for prophylaxis of acute viral respiratory tract infection in children]."
09/01/2003 - "The growth of leukemia was inhibited more obviously and the survival time of the leukemia-bearing nude mice was prolonged after im electroporation delivery of pcD2/hIFN-alpha 2 100 microg or 200 microg. "
09/01/2003 - "The pcD2/hIFN-alpha 2 was injected into the middle of the quadriceps muscle of female BALB/c mice or the leukemia-bearing female BALB/c nude mice, and then electroporation was given to the injection site. "
08/01/1992 - "We found that 10 of 11 acute leukemia cell lines with alterations of the IFNA/B genes were resistant to the antiproliferative effect of IFN alpha 2, whereas only two of eight cell lines with normal IFNA/B genes were IFN-resistant. "
08/01/1992 - "To test if selection against the IFN system was operating in acute leukemias, the sensitivity to the antiproliferative effect of IFN alpha 2 was studied in acute leukemia cell lines with and without alterations of the IFNA/B genes. "
09/01/2003 - "Electroporation was an efficient method for the delivery of plasmid DNA and im electroporation delivery of pcD2/hIFN-alpha 2 was effective in treating leukemia."
|3.||Suppositories (Vaginal Suppositories)
|4.||Recombinant DNA (Recombinant DNA Research)
|5.||Recombinant Interferon Type I
|8.||DNA (Deoxyribonucleic Acid)
|9.||Ribosomal DNA (rDNA)
|10.||Interferon-alpha (Interferon Alfa)
|2.||Self Administration (Administration, Self)
|5.||Investigational Therapies (Experimental Therapy)